Even et al. reported that 89Zr-cetuximab PET shows large interpatient variability in locally advanced HNSCCs and provides additional information about the accessibility of the drug into the tumor when compared with 18F-FDG PET and EGFR expression evaluated by ex vivo methods (26). The gene discussed is EGFR; the disease is neoplasm.